VISICORT PI Prof Thomas Ritter of the National University of Ireland Galway attended the kick-off meeting in Brussels of the COST Action Aniridia-NET: networking to address an unmet medical, scientific, and societal challenge. Aniridia is a devastating ocular disease that requires intensive eye care, social and community support from birth and throughout an individual’s lifetime.
Although a rare disease, aniridia is associated with ocular surface pathologies such as dry eye, inflammation, stem cell insufficiency, nerve degeneration, and vascularization – problems common to many ocular surface pathologies collectively affecting large populations. Greater collaboration and sharing of information and resources in the area of aniridia is therefore additionally expected to have significant benefits for the treatment of larger patient populations with ocular surface disease.
Two VISICORT PIs, Thomas Ritter and Jesper Hjortdal of Aarhus University Hospital are on the management committee of this project.
Learn more about the Aniridia-NET COST action CA 18116 here: https://bit.ly/2P6GTU3
Learn more about VISICORT at www.visicort.eu
VISICORT has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602470. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.